EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients—A Systematic Review and Meta-Analysis

Yu Jin Kim iD, Hee Min Lee iD, Ga Eun Lee, Jin Hui Yoo, Hwa Jeong Lee, Sandy Jeong Rhie iD

Pharmaceuticals · 21.08.2024 · 17 (8) · 1095

DOI: 10.3390/ph17081095 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 21.08.2024. Verfasst von Yu Jin Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: The study aimed to evaluate the efficacy and safety of incorporating bevacizumab into the combination therapy of carboplatin and paclitaxel for epithelial ovarian cancer and other clinical applications.

Methods

A systematic review was conducted following PRISMA guidelines using keyword searches in PubMed, Embase, Cochrane Library, CINAHL, ClinicalTrials.gov, and ICTRP until February 2024. Randomized controlled trials (RCTs) comparing carboplatin and paclitaxel with and without bevacizumab in ovarian cancer patients were included. Efficacy outcomes were overall survival (OS) and progression-free survival (PFS), as described by hazard ratios (HRs). Safety outcomes were analyzed with risk ratios (RRs) for 16 adverse events.

Results

Seven RCTs (n = 5110) were included. The combination with bevacizumab significantly improved PFS (HR: 0.73; 95% confidence interval: 0.58, 0.92; p = 0.008). The chemotherapy group receiving bevacizumab with carboplatin and paclitaxel showed a significantly higher incidence of hypertension, non-CNS bleeding, thromboembolic events, GI perforation, pain, and proteinuria.

Conclusions

The combination of carboplatin, paclitaxel, and bevacizumab improves PFS compared to the regimen without bevacizumab, but it raises significant safety concerns. Clinical management should consider adverse event prevention by vigilantly monitoring blood pressure, signs and symptoms of bleeding, thromboembolism, GI perforation, and pain to balance the therapeutic benefits with the potential risks of this combination therapy.

Schlagwörter

Stichwörter der Autor:innen

bevacizumabcarboplatinchemotherapyefficacyovarian cancerpaclitaxelsafety

Autor:innen und Institutionen

  • College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea.
  • Graduate School of Life and Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea.
  • Department of Pharmacy, Ewha Womans University Seoul Hospital, Seoul 07804, Republic of Korea.
  • Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea.

ORCID-Profile: Yu Jin Kim, Hee Min Lee, Sandy Jeong Rhie

Zitieren

APA

Kim, Y. J., Lee, H. M., Lee, G. E., Yoo, J. H., Lee, H. J., & Rhie, S. J. (2024). Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients—A Systematic Review and Meta-Analysis. Pharmaceuticals, 17(8), 1095. https://doi.org/10.3390/ph17081095

Vancouver

Kim YJ, Lee HM, Lee GE, Yoo JH, Lee HJ, Rhie SJ. Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients—A Systematic Review and Meta-Analysis. Pharmaceuticals. 2024;17(8):1095. doi:10.3390/ph17081095

BibTeX
@article{Kim2024,
  author = {Kim, Yu Jin and Lee, Hee Min and Lee, Ga Eun and Yoo, Jin Hui and Lee, Hwa Jeong and Rhie, Sandy Jeong},
  title = {Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients—A Systematic Review and Meta-Analysis},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {8},
  pages = {1095},
  doi = {10.3390/ph17081095}
}
Kostenlos starten →